生产企业：TREOS Bio
PolyPEPI-1018 is TREOS Bio's lead off-the-shelf multi-peptide immunotherapy candidate, developed using proprietary Promiscuous EPItopes (PEPI) Technology. It has been tested in three phase I/II clinical trials. The off-the-shelf design targets shared, non-mutated tumor antigens rather than patient-specific neoantigens, offering potential advantages in simpler logistics, faster treatment availability, and broader scalability compared to fully individualized approaches. TREOS Bio is now preparing to advance PolyPEPI1018 through Phase 2B clinical development in microsatellite-stable metastatic colorectal cancer (MSS mCRC).
PolyPEPI-1018 is TREOS Bio's lead off-the-shelf multi-peptide immunotherapy candidate, developed using proprietary Promiscuous EPItopes (PEPI) Technology. It has been tested in three phase I/II clinical trials. The off-the-shelf design targets shared, non-mutated tumor antigens rather than patient-specific neoantigens, offering potential advantages in simpler logistics, faster treatment availability, and broader scalability compared to fully individualized approaches. TREOS Bio is now preparing to advance PolyPEPI1018 through Phase 2B clinical development in microsatellite-stable metastatic colorectal cancer (MSS mCRC).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
